公开(公告)号：EP2480197B1

公开(公告)日：2015-11-11

申请号：EP10743228.8

申请日：2010-06-17

申请人： Dr. Reddy's Laboratories Ltd.

发明人： GANDHI, Rajesh ,  MANIKONDA, Sreekanth ,  JANA, Arun ,  KUNTE, Sameer, Shrinivas

IPC分类号： A61K9/00 ,  A61K31/40 ,  A61K31/70 ,  A61K47/26

CPC分类号： A61K31/4045 ,  A61K9/0043 ,  A61K31/40 ,  A61K31/404 ,  A61K31/70 ,  A61K31/7028 ,  A61K45/06 ,  A61K47/26 ,  A61K2300/00

摘要： The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

公开(公告)号：EP2480197A2

公开(公告)日：2012-08-01

申请号：EP10743228.8

申请日：2010-06-17

申请人： Dr. Reddy's Laboratories Ltd.

发明人： GANDHI, Rajesh ,  MANIKONDA, Sreekanth ,  JANA, Arun ,  KUNTE, Sameer, Shrinivas

IPC分类号： A61K9/00 ,  A61K31/40 ,  A61K31/70 ,  A61K47/26

CPC分类号： A61K31/4045 ,  A61K9/0043 ,  A61K31/40 ,  A61K31/404 ,  A61K31/70 ,  A61K31/7028 ,  A61K45/06 ,  A61K47/26 ,  A61K2300/00

摘要： The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

摘要翻译： 本发明提供了用于鼻内给药的药物组合物，其包含舒马普坦或其生理上可接受的溶剂化物的盐，烷基糖苷或糖烷基酯和任选的至少一种药学上可接受的赋形剂，其中所述组合物提供T max值小于30分钟 政府表示。 其他方面和实施例被考虑和描述。 本发明还提供了用于鼻内给药的药物组合物，其包含曲坦类，药学上可接受的载体和粘膜渗透促进剂，其中在所述施用后，所述组合物提供基本上与所述曲坦类的皮下施用相当的Tmax。 其他方面和实施例被考虑和描述。